U.S., Feb. 20 -- ClinicalTrials.gov registry received information related to the study (NCT07421011) titled 'Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat(R) 76,95 mg Orally Disintegrating Tablets and Trimedat(R) 100 mg Tablets in Healthy Volunteers.' on Jan. 15.
Brief Summary: This study aims to evaluate pharmacokinetic profile, safety and establish bioequivalence of the investigational drug Trimedat(R) 76,95 mg orally disintegrating tablets compared to the reference drug Trimedat(R) 100 mg tablets in healthy volunteers under fasted conditions.
Study Start Date: Nov. 06, 2025
Study Type: INTERVENTIONAL
Condition:
Irritable Bowel Syndrome
Gallstone Disease
GERD
Biliary Dyskinesia
Postcholecystectomy Syndrome
Intervent...